Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2024 | The unmet needs that remain for patients with systemic mastocytosis

Deepti Radia • 29 Apr 2024
BSH 2024
Myeloproliferative Neoplasms Rare Diseases Systemic Mastocytosis

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, briefly comments on the most significant unmet need for patients with systemic mastocytosis – receiving the correct diagnosis to ensure appropriate care is provided. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Disclosures: Blueprint Medicines / Cogent.

More from Deepti Radia

1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
1:27
Ongoing trials and novel agents being explored in advanced and indolent systemic mastocytosis
Deepti Radia • 30 Aug 2022
1:46
Unmet needs and challenges in advanced systemic mastocytosis
Deepti Radia • 30 Aug 2022

Related Videos

2:07
Treating young patients with MPN
Claire Harrison • 29 Apr 2024
2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:13
Current and emerging treatment options for patients with MF who are ineligible for ruxolitinib
Claire Harrison • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals